摩洛哥晚期帕金森病及设备辅助治疗资格的多中心横断面研究
包含摩洛哥帕金森病患者临床资料的多中心横断面数据集,用于评估晚期患者设备辅助治疗资格。

基本信息
资源简介
摩洛哥晚期帕金森病及设备辅助治疗资格的多中心横断面研究
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集,收录 3 个文件、合计 3.62 MB,主题涵盖 Advanced Parkinson’s disease、device-aided therapies、deep brain stimulation、levodopa-carbidopa intestinal gel、Morocco,可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study》。配套论文《Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study》发表于 Neurodegenerative Disease Management(2025),DOI:10.1080/17582024.2025.2481818。源站首次发布:2025-03-24。
【数据内容】
源站原始描述:This study investigates the prevalence and clinical features of advanced Parkinson’s disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG). We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and healt…
中文译文(机器翻译,仅供快速理解,请以原文为准):本研究探讨摩洛哥晚期帕金森病(APD)患者的患病率及临床特征,并评估其接受器械辅助治疗(DATs)的资格,包括脑深部电刺激(DBS)、持续皮下阿扑吗啡输注(CSAI)和左旋多巴-卡比多巴肠凝胶输注(LCIG)。 我们在摩洛哥卡萨布兰卡-塞塔特大区的五座城市、15家机构开展了一项横断面研究。我们收集了人口统计学、临床及健康相关生活质量数据。采用逻辑回归分析确定预测疾病进展及DATs资格的因素。 本研究纳入370例帕金森病患者,其中44.6%(95%CI:39.5%-49.8%)患有APD。病程每增加一年,APD风险增加8%(ORa = 1.08,p = 0.047)。总体而言,38.9%的患者符合至少一种DAT的条件,其中18.9%符合DBS、35.4%符合CSAI、13.8%符合LCIG;然而,仅1例患者接受了DBS。发病年龄越轻,DATs资格越高,每增加一年,资格降低7%(ORa = 0.93,p = 0.009),而既往有运动参与史使CSAI的几率几乎增至三倍(ORa = 2.87,p = 0.038)。 尽管许多摩洛哥患者符合DATs的条件,但其使用率极低。解决可及性障碍对于改善预后至关重要。
【数据结构与技术规格】
文件数 3 个,合计 3.62 MB。esup_1.pdf:application/pdf,184.94 KB。esup_2.pdf:application/pdf,638.89 KB。esup_3.pdf:application/pdf,2.79 MB。数据集 DOI:10.6084/m9.figshare.28652343.v1。
【主题与分类】
源站学科分类:Medicine、Chemical Sciences not elsewhere classified、Biological Sciences not elsewhere classified、Information Systems not elsewhere classified、Science Policy。主题标签:Advanced Parkinson’s disease、device-aided therapies、deep brain stimulation、levodopa-carbidopa intestinal gel、Morocco。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面:https://tandf.figshare.com/articles/dataset/Advanced_Parkinson_s_disease_and_eligibility_for_device-aided_therapies_in_Morocco_a_multicenter_cross-sectional_study/28652343
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study. Taylor & Francis. Daghi, Mohamed; Serhier, Zineb; Lakhdar, Abdelhakim; Otmani, Hicham El
【使用注意】
· 源站最后修改于 2025-11-14,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study
- DOI:10.6084/m9.figshare.28652343.v1
- 发布日期:2025-03-24
- 文件数:3 个
- 文件总体积:3.62 MB
- 源站页面:https://tandf.figshare.com/articles/dataset/Advanced_Parkinson_s_disease_and_eligibility_for_device-aided_therapies_in_Morocco_a_multicenter_cross-sectional_study/28652343
命令行下载
curl -L -o "esup_1.pdf" "https://ndownloader.figshare.com/files/53185365"
curl -L -o "esup_2.pdf" "https://ndownloader.figshare.com/files/53185368"
curl -L -o "esup_3.pdf" "https://ndownloader.figshare.com/files/53185371"
文件清单
esup_1.pdf(184.94 KB)esup_2.pdf(638.89 KB)esup_3.pdf(2.79 MB)
文件总体积 3.62 MB(源站 API 实测)。
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
This study investigates the prevalence and clinical features of advanced Parkinson’s disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG).
We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility.
This study included 370 patients with Parkinson’s disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038).
Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.28652343.v1(source: https://tandf.figshare.com/articles/dataset/Advanced_Parkinson_s_disease_and_eligibility_for_device-aided_therapies_in_Morocco_a_multicenter_cross-sectional_study/28652343)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




